Literature DB >> 27365132

Mitochondrial DNA haplogroups may influence Fabry disease phenotype.

C Simoncini1, L Chico1, D Concolino2, S Sestito2, L Fancellu3, W Boadu3, G P Sechi3, C Feliciani4, M Gnarra4, A Zampetti5, A Salviati6, M Scarpelli7, D Orsucci1, U Bonuccelli1, G Siciliano1, M Mancuso8.   

Abstract

While the genetic origin of Fabry disease (FD) is well known, it is still unclear why the disease presents a wide heterogeneity of clinical presentation and progression, even within the same family. Emerging observations reveal that mitochondrial impairment and oxidative stress may be implicated in the pathogenesis of FD. To investigate if specific genetic polymorphisms within the mitochondrial genome (mtDNA) could act as susceptibility factors and contribute to the clinical expression of FD, we have genotyped European mtDNA haplogroups in 77 Italian FD patients and 151 healthy controls. Haplogroups H and I, and haplogroup cluster HV were significantly more frequent in patients than controls. However, no correlation with gender, age of onset, organ involvement was observed. Our study seems to provide some evidence of a contribution of mitochondrial variation in FD pathogenesis, at least in Italy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Fabry; Haplogroups; Mitochondrial genotype; Oxidative stress; mtDNA

Mesh:

Substances:

Year:  2016        PMID: 27365132     DOI: 10.1016/j.neulet.2016.06.051

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Oxidative stress biomarkers in Fabry disease: is there a room for them?

Authors:  C Simoncini; S Torri; V Montano; L Chico; F Gruosso; A Tuttolomondo; A Pinto; I Simonetta; V Cianci; A Salviati; V Vicenzi; G Marchi; D Girelli; D Concolino; S Sestito; M Zedde; G Siciliano; Michelangelo Mancuso
Journal:  J Neurol       Date:  2020-07-27       Impact factor: 4.849

2.  Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells.

Authors:  Wei-Lien Tseng; Shih-Jie Chou; Huai-Chih Chiang; Mong-Lien Wang; Chian-Shiu Chien; Kuan-Hsuan Chen; Hsin-Bang Leu; Chien-Ying Wang; Yuh-Lih Chang; Yung-Yang Liu; Yuh-Jyh Jong; Shinn-Zong Lin; Shih-Hwa Chiou; Shing-Jong Lin; Wen-Chung Yu
Journal:  Cell Transplant       Date:  2016-12-06       Impact factor: 4.064

Review 3.  Fabry disease and kidney involvement: starting from childhood to understand the future.

Authors:  Roberto Chimenz; Valeria Chirico; Caterina Cuppari; Giorgia Ceravolo; Daniela Concolino; Paolo Monardo; Antonio Lacquaniti
Journal:  Pediatr Nephrol       Date:  2021-04-30       Impact factor: 3.651

4.  Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Authors:  Francesca Scionti; Maria Teresa Di Martino; Simona Sestito; Angela Nicoletti; Francesca Falvo; Katia Roppa; Mariamena Arbitrio; Pietro Hiram Guzzi; Giuseppe Agapito; Antonio Pisani; Eleonora Riccio; Daniela Concolino; Licia Pensabene
Journal:  Oncotarget       Date:  2017-11-18

5.  Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.

Authors:  Alena Jirásková; Giulia Bortolussi; Gabriela Dostálová; Lenka Eremiášová; Lubor Golaň; Vilém Danzig; Aleš Linhart; Libor Vítek
Journal:  Oxid Med Cell Longev       Date:  2017-08-16       Impact factor: 6.543

6.  Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease.

Authors:  Alaa Hamed; Pronabesh DasMahapatra; Nicole Lyn; Chad Gwaltney; Charlie Iaconangelo; Daniel Serrano; Vijay Modur; Juan Politei
Journal:  Mol Genet Metab Rep       Date:  2021-11-19

Review 7.  Anderson-Fabry Disease: From Endothelial Dysfunction to Emerging Therapies.

Authors:  Cosimo A Stamerra; Rita Del Pinto; Paolo di Giosia; Claudio Ferri; Amirhossein Sahebkar
Journal:  Adv Pharmacol Pharm Sci       Date:  2021-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.